Who are Triveni's investors?

Triveni's investors include Ascenta Capital, Atlas Venture, Borealis Ventures, Borealis Ventures, Magnetic Ventures, OrbiMed, Viking Global, Fidelity Investments and 3 more.

How much funding has Triveni raised?

Triveni has disclosed $65M raised across 1 round.

Triveni

58 employees on LinkedIn · 11 known investors

Find your way into Triveni

Paths you didn't know you had: your email and LinkedIn already hold routes to the Triveni team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases. The biotech company focuses on targeting the underlying biology of disease to change the standard of care for patients.

Biotech Digital Health Healthtech

Founders & leadership

Vishal PatelChief Executive OfficerVishal Patel is President and CEO of Triveni Bio, a clinical-stage biotech company developing antibody therapeutics for immunological and inflammatory disorders. He previously held venture capital roles at Atlas Ventures and Flagship Pioneering, executive positions at Novartis overseeing R&D strategy, and roles at Merck KGaA; his background also includes service with the U.S. Navy, the Defense Innovation Unit, the Office of the Secretary of Defense, and senior positions in the U.S. Senate and Department of State. He holds a BS in engineering from the University of Illinois, an MBA from MIT Sloan, and a PhD in biochemistry from Harvard University.

Investors · 11

Ascenta Capitallisted by Ascenta CapitalWilmington · $15M – $30M

How we know: Ascenta Capital's portfolio page · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Atlas Venturelisted by Atlas VentureCambridge · $500K – $1M

How we know: Atlas Venture's portfolio page · a partner's Signal profile · press coverage · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Borealis Ventureslisted by Borealis VenturesHanover · $1M – $2.5M

How we know: Borealis Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Borealis Ventureslisted by Borealis VenturesHanover

How we know: Borealis Ventures's portfolio page · Not right? Tell us

Magnetic Ventureslisted by Magnetic VenturesBoston · $1M – $6M

How we know: Magnetic Ventures's portfolio page · Not right? Tell us

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · press coverage · the VCSheet dataset · Not right? Tell us

Viking Globallisted by Viking GlobalStamford

How we know: Viking Global's portfolio page · Not right? Tell us

Fidelity InvestmentsreportedBoston

How we know: press coverage · Not right? Tell us

InvusreportedNew York

How we know: press coverage · Not right? Tell us

Janus Henderson InvestorsreportedLondon

How we know: funding news · Not right? Tell us

Viking Global InvestorsreportedStamford

How we know: press coverage · Not right? Tell us

Funding

SEC filings, press & company announcements

$65M disclosed across 1 round · 2026

$65MSeries CJun 2026 · 2 sources
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Triveni Bio Raises $65M in Series C Fundingfinsmes.com · Jun 2026

Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth - Triveni Biotriveni.bio · Jun 2026

Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disordersprnewswire.com · Oct 2024

Frequently asked questions

What does Triveni do?: Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases. The biotech company focuses on targeting the underlying biology of disease to change the standard of care for patients.
Who are Triveni's investors?: Triveni's investors include Ascenta Capital, Atlas Venture, Borealis Ventures, Borealis Ventures, Magnetic Ventures, OrbiMed, Viking Global, Fidelity Investments and 3 more.
How much funding has Triveni raised?: Triveni has disclosed $65M raised across 1 round.